© 2022 MJH Life Sciences and Contagion Live. All rights reserved.
© 2022 MJH Life Sciences™ and Contagion Live. All rights reserved.
Recommendations for managing patients with HIV infections with newer antiretroviral treatment options, including once-daily single-tablet regimens.
September 15th 2021
Strategies that can help physicians assess for HIV and talk with patients about concerns regarding quality-of-life issues.
Best practices for talking with patients about the importance of rapid initiation of therapy for HIV, and other important topics related to their treatment options.
September 21st 2021
The role of antiretroviral therapy and changes in lifestyle in the management of HIV infections.
A discussion regarding the risk of weight gain associated with antiretroviral therapies used to treat HIV infections.
September 28th 2021
The potential role of novel 2-drug regimens as treatment for HIV infections, and variables that impact a physician’s willingness to utilize over standard 3-drug options.
Reactions to the FDA approval of bictegravir, emtricitabine, and tenofovir alafenamide as fixed-dose combination therapy for patients with HIV.
October 5th 2021
Insight surrounding the use of a once daily, single-tablet combination of the protease inhibitor, darunavir, with cobicistat, emtricitabine, and tenofovir in patients with HIV.
Patient factors that impact the choice of therapeutic regimen to manage an HIV infection.
October 12th 2021
Adverse events associated with novel treatment regimens used to manage HIV infections, and advice regarding strategies that can be used to monitor for and manage patients.
Recommendations for properly assessing patients who are on HIV treatment for signs of potential weight gain.